Laboratory monitoring of chronic myelogenous leukemia patients on imatinib mesylate (Gleevec) therapy

被引：0
作者：
Shaw, GR [1 ]
机构：
[1] Marshfield Clin Fdn Med Res & Educ, Marshfield, WI USA
来源：
LABORATORY MEDICINE | 2004年 / 35卷 / 02期
关键词：
D O I：
10.1309/3JA20WEQ8PMT3JQC
中图分类号：
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号：
1001 ;
摘要：
引用
收藏
页码：104 / 106
页数：3
相关论文
共 12 条
  • [1] Hematopathologic and cytogenetic findings in imatinib mesylate-treated chronic myelogenous leukemia patients: 14 months' experience
    Braziel, RM
    Launder, TM
    Druker, BJ
    Olson, SB
    Magenis, RE
    Mauro, MJ
    Sawyers, CL
    Paquette, RL
    O'Dwyer, ME
    [J]. BLOOD, 2002, 100 (02) : 435 - 441
  • [2] Emergence of clonal cytogenetic abnormalities in Ph- cells in some CML patients in cytogenetic remission to imatinib but restoration of polyclonal hematopoiesis in the majority
    Bumm, T
    Müller, C
    Al-Ali, HK
    Krohn, K
    Shepherd, P
    Schmidt, E
    Leiblein, S
    Franke, C
    Hennig, E
    Friedrich, T
    Krahl, R
    Niederwieser, D
    Deininger, MWN
    [J]. BLOOD, 2003, 101 (05) : 1941 - 1949
  • [3] Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapy
    Cortes, JE
    Talpaz, M
    Giles, F
    O'Brien, S
    Rios, MB
    Shan, J
    Garcia-Manero, G
    Faclerl, S
    Thomas, DA
    Wierda, W
    Ferrajoli, A
    Jeha, S
    Kantarjian, HM
    [J]. BLOOD, 2003, 101 (10) : 3794 - 3800
  • [4] Hasserjian RP, 2002, AM J CLIN PATHOL, V117, P360
  • [5] Deletions of the derivative chromosome 9 occur at the time of the Philadelphia translocation and provide a powerful and independent prognostic indicator in chronic myeloid leukemia
    Huntly, BJP
    Reid, AG
    Bench, AJ
    Campbell, LJ
    Telford, N
    Shepherd, P
    Szer, J
    Prince, HM
    Turner, P
    Grace, C
    Nacheva, EP
    Green, AR
    [J]. BLOOD, 2001, 98 (06) : 1732 - 1738
  • [6] Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia.
    Kantarjian, H
    Sawyers, C
    Hochhaus, A
    Guilhot, F
    Schiffer, C
    Gambacorti-Passerini, C
    Niederwieser, D
    Resta, D
    Capdeville, R
    Zoellner, U
    Talpaz, M
    Druker, B
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (09) : 645 - 652
  • [7] LAWCE H, 2002, J ASS GENET TECHNOL, V28, P40
  • [8] Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia
    O'Brien, SG
    Guilhot, F
    Larson, RA
    Gathmann, I
    Baccarani, M
    Cervantes, F
    Cornelissen, JJ
    Fischer, T
    Hochhaus, A
    Hughes, T
    Lechner, K
    Nielsen, JL
    Rousselot, P
    Reiffers, J
    Saglio, G
    Shepherd, J
    Simonsson, B
    Gratwohl, A
    Goldman, JM
    Kantarjian, H
    Taylor, K
    Verhoef, G
    Bolton, AE
    Capdeville, R
    Druker, BJ
    Durrant, S
    Schwarer, A
    Joske, D
    Seymour, J
    Grigg, A
    Ma, D
    Arthur, C
    Bradstock, K
    Joshua, D
    Louwagie, A
    Martiat, P
    Straetmans, N
    Bosly, A
    Shustik, C
    Lipton, J
    Forrest, D
    Walker, I
    Roy, DC
    Rubinger, M
    Bence-Bruckler, I
    Kovacs, M
    Turner, AR
    Birgens, H
    Bjerrum, O
    Facon, T
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (11) : 994 - 1004
  • [9] The impact of clonal evolution on response to imatinib mesylate (ST1571) in accelerated phase CML
    O'Dwyer, ME
    Mauro, MJ
    Kurilik, G
    Mori, M
    Balleisen, S
    Olson, S
    Magenis, E
    Capdeville, R
    Druker, BJ
    [J]. BLOOD, 2002, 100 (05) : 1628 - 1633
  • [10] Drug therapy: Imatinib mesylate - A new oral targeted therapy.
    Savage, DG
    Antman, KH
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (09) : 683 - 693
12